United Health Products (UEEC) 10-K1 Apr 222021 FY Annual reportFinancial data

Company Profile

Cover

Cover - USD ($)	12 Months Ended
Cover - USD ($)	Dec. 31, 2021	Mar. 31, 2022	Jun. 30, 2021
Cover [Abstract]
Entity Registrant Name	UNITED HEALTH PRODUCTS, INC.
Entity Central Index Key	0001096938
Document Type	10-K
Amendment Flag	false
Entity Voluntary Filers	No
Current Fiscal Year End Date	--12-31
Entity Well Known Seasoned Issuer	No
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Dec. 31, 2021
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Entity Common Stock Shares Outstanding		228,829,891
Entity Public Float			$ 189,613,121
Document Annual Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Entity File Number	000-27781
Entity Tax Identification Number	84-1517723
Entity Incorporation State Country Code	NV
Entity Address Address Line 1	10624 S. Eastern Avenue
Entity Address Address Line 2	Ste. A209
Entity Address City Or Town	Henderson
Entity Address State Or Province	NV
Entity Address Postal Zip Code	89052
City Area Code	877
Local Phone Number	358-3444
Auditor Name	Mac Accounting Group, LLP
Auditor Location	Midvale, Utah
Auditor Firm Id	6258

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current Assets
Cash and Cash Equivalents	$ 21,799	$ 46,076
Inventory	0	69,674
Prepaid and other current assets	5,000	0
Total current assets	26,799	115,750
Property and equipment	0	101,350
TOTAL ASSETS	26,799	217,100
Current Liabilities
Accounts payable and accrued expenses	826,486	416,759
Accrued liabilities - related parties	3,207	193,651
Accrued litigation settlement	120,000	0
Loan payable - related party	219,000	0
Convertible notes payable, net of debt discount	0	103,920
Convertible notes payable - related party, net of debt discount	0	456,032
Total current liabilities	1,168,693	1,170,362
TOTAL LIABILITIES	1,168,693	1,170,362
Commitments and Contingencies	0	0
Stockholders' Deficit
Series A Convertible Preferred Stock - $.001 par value, 1,000,000 shares Authorized and 0 shares issued and outstanding	0	0
Common Stock - $.001 par value, 300,000,000 shares Authorized, 228,667,229 and 189,357,090 shares issued and outstanding at December 31, 2021 and December 31, 2020	228,667	189,357
Additional Paid-In Capital	71,017,881	40,696,640
Accumulated Deficit	(72,388,442)	(41,839,259)
Total Stockholders' Deficit	(1,141,894)	(953,262)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 26,799	$ 217,100

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Stockholders' Deficiency
Common stock, shares par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	228,667,229	189,357,090
Common stock, shares outstanding	228,667,229	189,357,090
Series A Convertible Preferred Stock [Member]
Stockholders' Deficiency
Preferred Stock, shares par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
Statements of Operations - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Statements of Operations
Revenues	$ 59	$ 643
Cost of sales	25	195
Gross profit	34	448
Operating Costs and Expenses
Selling, general and administrative expenses	29,563,211	14,603,881
Research and development expenses	237,458	245,218
Total Operating Expenses	29,800,669	14,849,099
Loss from Operations	(29,800,635)	(14,848,651)
Other income (expenses)
Interest expense	(226,139)	(210,025)
Interest expense - related party	(392,112)	(336,203)
Loss on settlement of debt	(434,570)	(316,521)
Other income	304,273	0
Total other income (expense)	(748,548)	(862,749)
Income tax expense	0	0
Net Loss	$ (30,549,183)	$ (15,711,400)
Net Loss per common share:
Basic and diluted	$ (0.14)	$ (0.09)
Weighted average number of shares outstanding	225,741,684	183,756,271

Statement of Stockholders Equit

Statement of Stockholders Equity - USD ($)	Total	Common Stock [Member]	Additional Paid-In Capital	Accumulated Deficit
Balance, shares at Dec. 31, 2019		178,300,337
Balance, amount at Dec. 31, 2019	$ (903,805)	$ 178,300	$ 25,045,754	$ (26,127,859)
Beneficial conversion feature	909,565	$ 0	909,565	0
Issuance of common stock for services, shares		425,000
Issuance of common stock for services, amount	301,875	$ 425	301,450	0
Stock-based compensation on vesting of restricted stock units, shares		7,595,000
Stock-based compensation on vesting of restricted stock units, amount	12,420,930	$ 7,595	12,413,335	0
Issuance of common stock for debt, shares		1,058,634
Issuance of common stock for debt, amount	866,482	$ 1,059	865,423	0
Sale of common stock, shares		2,000,500
Sale of common stock, amount	1,130,696	$ 2,000	1,128,696	0
Cancelled shares, shares		(22,381)
Cancelled shares, amount	0	$ (22)	22	0
Forgiveness of related party debt	32,395	0	32,395	0
Net Loss	(15,711,400)	$ 0		(15,711,400)
Balance, shares at Dec. 31, 2020		189,357,090
Balance, amount at Dec. 31, 2020	(953,262)	$ 189,357	40,696,640	(41,839,259)
Beneficial conversion feature	234,912	$ 0	234,912	0
Issuance of common stock for debt, shares		300,000
Sale of common stock, shares		556,455
Sale of common stock, amount	479,802	$ 557	479,245	0
Cancelled shares, shares		(117,647)
Cancelled shares, amount	0	$ (118)	118	0
Forgiveness of related party debt	0
Net Loss	(30,549,183)	$ 0		(30,549,183)
Issuance of common stock for services and compensation, shares		34,715,000
Issuance of common stock for services and compensation, amount	26,861,097	$ 34,715	26,826,382	0
Common stock issued for litigation settlement, amount	312,000	$ 300	311,700	0
Common stock issued to settle accrued liabilities - related party, shares		1,013,085
Common stock issued to settle accrued liabilities - related party, amount	867,368	$ 1,013	866,355	0
Common stock issued to settle related party advances, shares		25,000
Common stock issued to settle related party advances, amount	26,750	$ 25	26,725	0
Common stock issued to settle accrued liabilities, shares		380,000
Common stock issued to settle accrued liabilities, amount	311,600	$ 380	311,220	0
Common stock issued for conversion of convertible notes payable and accrued interest, shares		1,085,135
Common stock issued for conversion of convertible notes payable and accrued interest, amount	590,467	$ 1,085	589,382	0
Common stock issued for conversion of convertible notes payable and accrued interest - related party, shares		1,353,111
Common stock issued for conversion of convertible notes payable and accrued interest - related party, amount	676,555	$ 1,353	675,202	0
Balance, shares at Dec. 31, 2021		228,667,229
Balance, amount at Dec. 31, 2021	$ (1,141,894)	$ 228,667	$ 71,017,881	$ (72,388,442)

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
Statements of Cash Flows - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Cash Flows from Operating Activities:
Net Loss	$ (30,549,183)	$ (15,711,400)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Stock for services and compensation	26,861,097	12,722,805
Loss on settlement of debt	434,570	316,521
Write-off of inventory	69,649	6,979
Write-off of property and equipment	101,350	0
Stock issued for litigation settlement	312,000	0
Amortization of debt discount	608,710	535,766
Changes in assets and liabilities:
Inventory	25	195
Prepaid and other current assets	(5,000)	0
Accounts payable and accrued expenses	693,692	360,465
Accrued litigation settlement	120,000	0
Accrued liabilities - related party	525,011	442,807
Net Cash Used In Operating Activities	(828,079)	(1,325,862)
Cash Flows from Investing Activities:
Purchase of property and equipment	0	(101,350)
Net Cash Used In Investing Activities	0	(101,350)
Cash Flows from Financing Activities:
Repayment to related parties	(36,500)	(505,762)
Proceeds from related parties	245,500	251,730
Proceeds from convertible notes payable - related party	0	580,000
Proceeds from convertible notes payable	115,000	0
Proceeds from issuance of common stock	479,802	1,130,696
Net Cash Provided By Financing Activities	803,802	1,456,664
Increase (decrease) in Cash and Cash Equivalents	(24,277)	29,452
Cash and Cash Equivalents - Beginning of period	46,076	16,624
CASH AND CASH EQUIVALENTS - END OF PERIOD	21,799	46,076
Supplemental cash flow information:
Cash paid for interest	0	0
Cash paid for income taxes	0	0
Schedule of Non-Cash Financing Activities:
Cancellation of common stock	117	22
Forgiveness of related party debt	0	32,395
Common stock issued for notes payable and accrued liabilities - related party	561,148	0
Common stock issued to settle accounts payable and accrued liabilities	190,000	0
Common stock issued for debt	0	549,567
Debt discount related to beneficial conversion feature	234,912	909,565
Conversion of accounts payable and accrued liabilities to convertible notes payable	90,000	250,000
Accounts payable and accrued liabilities - related party converted to convertible notes payable - related party	112,500	258,750
Accrued liabilities - related party converted to	0	100,000
Conversion of accrued liabilities - related party to loans payable - related parties	30,000	0
Common stock issued to settle related party advances	20,000	0
Common stock issued for conversion of convertible notes payable and accrued interest	590,467	0
Common stock issued for conversion of convertible notes payable and accrued interest - related party	676,555	0
Convertible notes payable and accrued interest- related party converted to convertible notes payable and accrued interest	$ 176,502	$ 198,778

Description of the Business

Description of the Business	12 Months Ended
Description of the Business	Dec. 31, 2021
Description of the Business
Note 1. Description of the Business	Note 1. Description of the Business United Health Products, Inc. (the “Company”) develops, manufactures, and markets a patented hemostatic gauze for the healthcare and wound care sectors. Our gauze product, HemoStyp®, is a neutralized, oxidized, regenerated cellulose (“NORC”) derived from cotton and designed to absorb exudate/drainage from superficial wounds and help control bleeding. We are in the process of seeking regulatory approval to sell our Hemostyp product line into the U.S. Class III and European Union CE Mark surgical market.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
Significant Accounting Policies	Dec. 31, 2021
Significant Accounting Policies
Note 2. Significant Accounting Policies	Note 2. Significant Accounting Policies Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred recurring net losses, negative working capital and operations have not provided cash flows. Additionally, the Company does not currently have sufficient revenue producing operations to cover its operating expenses and meet its current obligations. In view of these factors, there is substantial doubt about the Company's ability to continue as a going concern. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital and other business requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. On March 11, 2020, the World Health Organization declared the outbreak of a coronavirus (COVID-19) as a pandemic. As a result, economic uncertainties have arisen which have the potential to negatively impact the Company’s ability to raise funding. Other factors that carry financial implications for the Company could occur although the potential impacts are unknown at this time. Basis of Presentation The Company prepares its financial statements on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported period. Changes in the economic environment, financial markets, as well as in the healthcare industry, and any other parameters used in determining these estimates, could cause actual results to differ. Cash and Cash Equivalents The Company considers all highly liquid debt investments purchased with a maturity of three months or less to be cash equivalents. Fair Value Measurements Accounting principles generally accepted in the United States define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Additionally, the inputs used to measure fair value are prioritized based on a three-level hierarchy. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: Level 1 — Quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs other than quoted prices included in Level 1. We value assets and liabilities included in this level using dealer and broker quotations, bid prices, quoted prices for similar assets and liabilities in active markets, or other inputs that are observable or can be corroborated by observable market data. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2021 and 2020. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. Income Taxes The Company accounts for income taxes using a method that requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company’s assets and liabilities which is commonly known as the asset and liability method. In assessing the ability to realize deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company evaluates its tax positions taken or expected to be taken in the course of preparing the Company’s tax returns to determine whether the tax positions are ‘‘more-likely-than-not’’ of being sustained by the applicable tax authority. Tax positions not deemed to meet the “more-likely-than-not” threshold are recorded as an expense in the applicable year. The Company does not have a liability for any unrecognized tax benefits. Management’s evaluation of uncertain tax positions may be subject to review and adjustment at a later date based upon factors including, but not limited to, an on-going analysis of tax laws, regulations and interpretations thereof, with due consideration given to the fact that tax periods are open to examination by tax authorities. As of December 31, 2021 and 2020, the Company has approximately $20.0 and $17.8 million of net operating loss carry-forwards, respectively, available to affect future taxable income and has established a valuation allowance equal to the tax benefit of the net operating loss carry forwards and temporary differences as realization of the asset is not assured. Revenue Recognition The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers The Company receives orders for its HemoStyp products directly from its customers. Revenues are recognized based on the agreed upon sales or transaction price with the customer when control of the promised goods are transferred to the customer. The transfer of goods to the customer and satisfaction of the Company’s performance obligation will occur either at the time when products are shipped or when the products arrive and are received by the customer depending on the shipping terms. No discounts are offered by the Company as part of payment terms. The Company does not provide an estimate for returns as there is no anticipation for any returns in the normal course of business. Trade Accounts Receivable and Concentration Risk We record accounts receivable at the invoiced amount and we do not charge interest. We review the accounts receivable by amounts due from customers which are past due to identify specific customers with known disputes or collectability issues. In determining the amount of the reserve, we make judgments about the creditworthiness of significant customers based on ongoing credit evaluations. We will also maintain a sales allowance to reserve for potential credits issued to customers. We will determine the amount of the reserve based on historical credits issued. There was no provision for doubtful accounts recorded at December 31, 2021 and 2020. The Company recorded $0 in bad debt expense for the years ended December 31, 2021 and 2020. For the year ended December 31, 2021 one customer accounted for 100% of the Company’s net revenue. For the year ended December 31, 2020 one customer accounted for 100% of the Company’s net revenue. Inventory Inventory is valued at the lower of cost or net realizable value using the first-in, first-out (FIFO) method. Inventory on the balance sheet consists of raw materials purchased by the Company and finished goods. December 31, 2021 December 31, 2020 Raw materials $ - $ 50,654 Finished goods - 19,020 $ - $ 69,674 During the years ended December 31, 2021 and 2020, the Company determined that $69,649 and $6,979, needed to be impaired and written-off, respectively. Advertising and Marketing Costs Shipping and Handling Costs The Company includes shipping and handling cost as part of cost of goods sold. Research and Development The Company charges research and development costs to expense when incurred. The Company incurred $237,458 and $245,218 in research and development expenses during the years ended December 31, 2021 and 2020, respectively. Stock Based Compensation The Company accounts for share-based compensation under the provisions of ASC 718, Compensation-Stock Compensation The Company accounts for stock compensation arrangements with non-employees in accordance with Accounting Standard Update (ASU) 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, Per Share Information Basic earnings per share are calculated using the weighted average number of common shares outstanding for the period presented. Diluted earnings per share is computed using the weighted-average number of common shares and, if dilutive, potential common shares outstanding during the period. The dilutive effect of potential common shares is not reflected in diluted earnings per share because the Company incurred a net loss for the years ended December 31, 2021 and 2020 and the effect of including these potential common shares in the net loss per share calculations would be anti-dilutive. The total potential common shares as of December 31, 2021 include 28,190,000 of restricted stock units. The total potential common shares as of December 31, 2020 include 59,330,000 of restricted stock units and 1,867,500 shares of common stock for convertible notes payable – related party. Property and Equipment Property and equipment are stated at cost. Depreciation is computed on the straight-line method. The depreciation and amortization methods are designed to amortize the cost of the assets over their estimated useful lives, in years, of the respective assets as follows: Equipment 10 years Maintenance and repairs are charged to expense as incurred. Improvements of a major nature are capitalized. At the time of retirement or other disposition of property and equipment, the cost and accumulated depreciation are removed from the accounts and any gains or losses are reflected in income. Impairment of Long-lived Assets The Company applies the provisions of ASC 360, Property, Plant and Equipment, When equipment is sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is included in the results of operations. During the years ended December 31, 2021 and 2020 the Company determined its property and equipment should be impaired and $101,350 and $0 was written off, respectively. New Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) No. ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, Under current GAAP, there are five accounting models for convertible debt instruments. ASU 2020-06 removes from U.S. GAAP the separation models for (1) convertible debt with a cash conversion feature and (2) convertible instruments with a beneficial conversion feature. As a result, after adopting the ASU’s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC 815 or (2) a convertible debt instrument was issued at a substantial premium. Additionally, for convertible debt instruments with substantial premiums accounted for as paid-in capital, the FASB decided to add disclosures about (1) the fair value amount and the level of fair value hierarchy of the entire instrument for public business entities and (2) the premium amount recorded as paid-in capital. ASU 2020-06 will be effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the potential impact of the adoption of this accounting pronouncement to its financial statements. The Company considers all new pronouncements and management has determined that there have been no other recently adopted or issued accounting standards that had or will have a material impact on its financial statements.

Related Party Transactions

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2021
Related Party Transactions
Note 3. Related Party Transactions	Note 3. Related Party Transactions Related party convertible notes payables As of December 31, 2021 and 2020, convertible notes payable – related parties totaled $0 and $456,032, respectively. During the year ended December 31, 2020, Mr. Beplate loaned the Company $251,730 which was convertible at $0.65. These loans resulted in a beneficial conversion feature of $83,156 which was recorded to interest expense – related party upon issuance. The Company made repayments to Mr. Beplate totaling $505,765, $87,750 was assigned to the Company’s legal counsel and $24,000 was forgiven during the year ended December 31, 2020, leaving a balance of $0 owed to Mr. Beplate as of December 31, 2020. These loans were made to pay for operating expenses of the Company, due on demand and carried no interest rate. During the year ended December 31, 2020, Brian Thom, the Chief Executive Officer loaned the Company $450,000 and also converted $105,000 of accrued compensation into a convertible note. The note and loans were convertible at $0.50 per share at the discretion of the Mr. Thom, had a maturity date of March 31, 2021 and carried an interest rate of 3%. The loans resulted in a beneficial conversion feature totaling $338,105 which was recorded as a debt discount. The debt discount was amortized through the maturity dates and $138,792 was amortized to interest expense – related party during the year ended December 31, 2020. As of December 31, 2020, the total outstanding balance of the note and loans was $555,000 and the remaining unamortized debt discount was $199,314. During the year ended December 31, 2021, Mr. Thom converted $45,000 of accrued compensation into a convertible note. The note was convertible at $0.50 per share at the discretion of Mr. Thom, had a maturity date of March 31, 2021 and carried an interest rate of 3%. The note resulted in a beneficial conversion feature of $45,000 which was recorded as a debt discount. The debt discount was amortized through the maturity date and a total of $244,314 for all of Mr. Thom’s notes was amortized to interest expense – related party during the year ended December 31, 2021, which included the unamortized debt discount of $199,314 as of December 31, 2020 and the debt discount of $45,000 recorded during the current year. The remaining unamortized debt discount is $0. The total outstanding principal balance of $600,000 which was related to $450,000 of loans to the Company and $150,000 of accrued compensation along with accrued interest of $10,135 was converted into 1,220,272 shares of common stock leaving $0 owed to Mr. Thom as of December 31, 2021. During the year ended December 31, 2020, Louis Schiliro, the Chief Operating Officer loaned the Company $130,000 and also converted $150,000 of accrued compensation into a convertible note. The note and loans are convertible at $0.50 per share at the discretion of Mr. Schiliro, have a maturity date of March 31, 2021 and have an interest rate of 3%. During the year ended December 31, 2020, $110,000 of the convertible note payable along with $1,028 of accrued interest was assigned to the Company’s legal counsel leaving a total outstanding balance of the note and loans of $170,000. The loans and note resulted in a beneficial conversion feature totaling $174,985 which was recorded as a debt discount. The debt discount was amortized through the maturity dates and $105,331 was amortized to interest expense – related party during the year ended December 31, 2020. During the year ended December 31, 2021, Mr. Schiliro converted $45,000 of accrued compensation into a convertible note. The note was convertible at $0.50 per share at the discretion of Mr. Schiliro, had a maturity date of March 31, 2021 and carried an interest rate of 3%. The note resulted in a beneficial conversion feature of $45,000 which was recorded as a debt discount. The debt discount was amortized through the maturity date and a total of $114,654 for all of Mr. Schiliro’s notes was amortized to interest expense – related party during the year ended December 31, 2021, which included the unamortized debt discount of $69,654 as of December 31, 2020 and the debt discount of $45,000 recorded during the current year. The remaining unamortized debt discount is $0. During the year ended December 31, 2021, $175,000 of the convertible note payable along with $1,502 of accrued interest was assigned to one of the Company’s legal counsel leaving a total outstanding balance of $40,000. The remaining balance of $40,000 along with accrued interest was converted into 80,173 shares of common stock leaving $0 owed to Mr. Schiliro as of December 31, 2021. During the year ended December 31, 2020, Kristofer Heaton, the Principal Financial Officer, converted $3,750 of accrued compensation into a convertible loan. The loan was convertible at $0.50 per share at the discretion of Mr. Heaton, had a maturity date of March 31, 2021 and carried an interest rate of 3%. This note resulted in a beneficial conversion feature totaling $3,750 which was recorded as a debt discount. The debt discount is being amortized through the maturity date and $0 was amortized to interest expense – related party during the year ended December 31, 2020. During the year ended December 31, 2021, Mr. Heaton, converted $22,500 of accrued compensation into a convertible note. The note was convertible at $0.50 per share at the discretion of Mr. Heaton, had a maturity date of March 31, 2021 and carried an interest rate of 3%. The note resulted in a beneficial conversion feature totaling $22,500 which was recorded as a debt discount. The debt discount is being amortized through the maturity date and a total of $26,250 for all of Mr. Heaton’s notes was amortized to interest expense – related party during the year ended December 31, 2021, which included the unamortized debt discount of $3,750 as of December 31, 2020 and the debt discount of $22,500 recorded during the current period. The remaining unamortized debt discount is $0. The total outstanding principal balance of $26,250 along with accrued interest was converted into 52,666 shares of common stock leaving $0 owed to Mr. Heaton as of December 31, 2021. Interest expense – related party on the above convertible notes was $392,112 ($6,894 interest expense along with $385,218 of debt discount amortization) and $336,203 ($8,925 interest expense along with $327,278 of debt discount amortization) during the years ended December 31, 2021 and 2020, respectively. Accrued interest – related party due to these convertible notes was $2,308 and $7,503 as of December 31, 2021 and 2020, respectively. Loans payable/Advances from related parties During the year ended December 31, 2021, Mr. Schiliro advanced the Company $34,000 to pay for operating expenses and paid $30,000 of expenses on behalf of the Company. During the year ended December 31, 2021, the Company issued 25,000 shares of common stock to settle $20,000 of the outstanding balance. The shares of common stock had a fair market value of $26,750 and the Company recorded a loss on debt settlement of $6,750. As of December 31, 2021 and December 31, 2020, the balance owed to Mr. Schiliro was $44,000 and $0, respectively. These amounts were converted to a loan payable and have an interest rate of 10% and are due on demand. During the year ended December 31, 2021, Mr. Thom loaned the Company a total of $175,000 to pay for operating expenses. As of December 31, 2021, the amount of $175,000 is owed to Mr. Thom. The loans have an interest rate of 10% and are due on demand. Interest expense – related party on the above loans payable – related party was $2,308 during the year ended December 31, 2021 leaving an accrued interest – related party balance of $2,308. Accrued liabilities During the year ended December 31, 2020, $188,375 was paid to Mr. Beplate, $100,000 of accrued compensation was converted to a convertible note payable and then assigned to the Company’s legal counsel and $8,395 of accrued compensation was forgiven. The note was convertible at $0.50 per share at the discretion of the note holder, had a maturity date of March 31, 2021 and carried an interest rate of 3%. The note resulted in a beneficial conversion feature totaling $100,000 which was recognized into interest expense. As of December 31, 2021 and 2020, $0 and $0 was owed to Mr. Beplate, respectively. As of December 31, 2021 and December 31, 2020, $0 and $74,056 was owed to Nate Knight, who was the Company’s Chief Financial Officer until November 2020, for accrued compensation and reimbursable expenses. During the year ended December 31, 2021, the Company issued 78,500 shares of common stock to settle the total balance owed of $74,056. The shares of common stock had a fair market value of $82,425 and the Company record a loss on debt settlement of $8,368. As of December 31, 2021 and December 31, 2020, $899 and $0 was owed to Brian Thom, the Chief Executive Officer, for accrued compensation and reimbursable expenses. During the years ended December 2021 and 2020, $45,000 and $105,000 of compensation were converted into convertible loans as mentioned above. In the year ended December 31, 2021, $135,000 of accrued compensation was settled with the issuance of 270,000 shares of common stock. The stock had a fair market value of $221,400 which resulted in a $86,400 loss on settlement of debt (see Note 6). As of December 31, 2021 and December 31, 2020, $0 and $59,467 was owed to Louis Schiliro, the Chief Operating Officer, for accrued salary and reimbursable expenses, respectively. During the years ended December 31, 2021 and 2020, $45,000 and $150,000 of compensation were converted into a convertible loan as mentioned above and in the year ended December 31, 2020 $30,000 was paid in cash. During the year ended December 31, 2021, the Company issued 74,335 shares of common stock to settle the total prior year balance owed of $59,467 and issued 270,000 shares of common stock to settle $135,000 of accrued compensation. The shares of common stock had a total fair market value of $300,938 and the Company recorded a loss on settlement of debt in the amount of $106,471 (see Note 6). As of December 31, 2021 and December 31, 2020, $0 and $52,625 was owed to Mr. Heaton, for accrued compensation and services provided. During the years ended December 31, 2021 and 2020, $22,500 and $3,750 of compensation were converted into a convertible note as described above. During the year ended December 31, 2021, 320,250 shares of common shares of stock were issued to settle $105,000 of accrued compensation and $52,625 of prior accruals. The shares of common stock had a total fair market value of $262,605 and the Company recorded a loss on settlement of debt in the amount of $104,980 (see Note 6). Equity transactions On July 21, 2020, the Board of Directors approved amendments to RSU Agreements put in place on March 25, 2019 (“2019 RSU Agreement”). The approved amendments increased the amount of RSU’s granted to Mr. Beplate from 33,000,000 to 33,800,000, increased the amount of RSU’s granted to Mr. Schiliro from 8,000,000 to 10,000,000, increased the amount of RSU’s granted to Mr. Heaton from 50,000 to 500,000, increased the amount of RSU’s granted to the office administrator, who is a person affiliated with the Company’s former CEO from 250,000 to 500,000 and increased the amount of RSU’s granted to the Technical Product Supervisor, who is the son of the former office administrator from 250,000 to 500,000. The July 21 amendment also changed the vesting terms so that 15% of RSUs vested on July 15, 2020, an additional 15% of RSU units upon FDA approval of a PMA Class III awarded to the Company, an additional 20% of RSU units on January 1, 2021 and the balance of all unvested RSU units on the earliest date that (a) the Company achieves $20 million in gross cumulative sales commencing as of January 1, 2020, (b) a Covered Transaction is consummated or (c) a Trigger Event occurs. Each Grantee has the option to delay the Vesting Date of all or part of his RSUs until no later than an event described in (b) or (c) above, by serving written notice to the Company prior to such Vesting Date. The change in vesting terms resulted in a total of 6,795,000 of the RSU’s vesting on July 15, 2020 with 5,070,00 being issued to Mr. Beplate, 1,500,000 being issued to Mr. Schiliro, 75,000 being issued to Mr. Heaton, 75,000 being issued to the former office administrator, who is a person affiliated with the Company’s former CEO and 75,000 being issued to the Technical Product Supervisor, who is the son of the former office administrator. The change in vesting terms also resulted in a total of 50,000 of the RSU’s vesting on July 20, 2020 with 50,000 being issued to the Marketing and Advertising Supervisor, who is the daughter of the former office administrator. The vesting of the 6,845,000 RSU’s resulted in stock-based compensation expense of $4,859,950 which was the fair value of the stock on the vesting date. The former office administrator resigned during the year ended December 31, 2020 and forfeited 425,000 of the remaining unvested RSU’s with a value of $301,750 ($70,567 of which had been recognized and reversed). In November 2020, the Company granted Mr. Thom 11,500,000 RSU’s which subject to certain conditions, shall vest upon the achievement of certain Company objectives and milestones. In December 2020, the Company entered into a second restricted stock unit agreement with Mr. Heaton. The second agreement issued an additional 1,000,000 RSU’s, 500,000 of which were granted on the award date and 500,000 of which would be granted on May 15, 2021 provided his professional services agreement was in effect on that date. The 500,000 RSU’s were granted during 2021 per the agreement. The RSU’s, subject to certain conditions, shall vest upon the achievement of certain Company objectives and milestones. During the year ended December 31, 2020, the Company issued a total of 125,000 shares of restricted common stock to Mr. Thom, prior to becoming Chief Executive Officer, for services rendered. The shares had a fair market value of $100,625. Per the vesting schedules of certain of the Company’s amended RSU Agreements, on January 1, 2021, 6,760,000 shares of common stock were issued to Mr. Beplate, 2,000,000 shares of common stock were issued to Mr. Schiliro and 100,000 shares of common stock were issued to Mr. Heaton. On January 6, 2021, the Board of Directors approved the second amendment to the RSU Agreement between the Company and Mr. Beplate in conjunction with Mr. Beplate’s retirement from his day-to-day management role with the Company. The amendment accelerated the vesting and immediately settled his remaining RSU’s by issuing 21,970,000 shares of common stock. Further, as a bonus in recognition of Mr. Beplate’s service to the Company and in recruitment of new executive management, the Company issued to Mr. Beplate an additional 2,000,000 shares of common stock. The Company recorded $26,127,300 of stock-based compensation expense during the year ended December 31, 2021 related to the accelerated vesting of these RSU’s and issuance of common stock. During the year ended December 31, 2021, the Company issued 30,000 shares of common stock to Mr. Thom, 30,000 shares of common stock to Mr. Schiliro and 25,000 shares of common stock to Mr. Heaton for services rendered. The 85,000 shares of common stock had a total fair market value of $69,700.

Convertible Notes

Convertible Notes	12 Months Ended
Convertible Notes	Dec. 31, 2021
Convertible Notes
Note 4. Convertible Notes	Note 4. Convertible Notes Convertible notes 2020 During the year ended December 31, 2020, certain service providers and a medical advisor converted $205,000 of accrued compensation into convertible notes. The notes were convertible at $0.50 per share at the discretion of the note holders, had a maturity date of March 31, 2021 and carried an interest rate of 3%. As of December 31, 2020, the convertible loans had a principal balance of $205,000 and the balance on the loans net of the debt discount was $103,920 During the year ended December 31, 2020, the Company’s legal counsel was assigned $298,778 worth of loans after paying various outstanding balances on behalf of the Company. In addition, the Company’s legal counsel converted $45,000 of accrued fees into a convertible note payable. The note was convertible at $0.50 per share at the discretion of the note holder, had a maturity date of March 31, 2021 and carried an interest rate of 3%. The note resulted in a beneficial conversion feature totaling $45,000 which was recorded as a debt discount, to be amortized through its maturity date. The Company’s legal counsel converted all of the convertible loans into 557,056 shares of common stock in accordance with the original conversion features of the notes, therefore no gain or loss on debt settlement was recognized and the total debt discount of $45,000 was recognized into interest expense. As of December 31, 2020, no amounts were owing to the Company’s legal counsel related to these transactions. Interest expense was $1,537 and $0 during the year ended December 31, 2020 and the entire amount was accrued. Convertible notes 2021 During the year ended December 31, 2021, the service providers and medical advisor converted $90,000 of accrued compensation into convertible notes. The notes were convertible at $0.50 per share at the discretion of the note holders, had a maturity date of March 31, 2021 and carried an interest rate of 3%. These notes resulted in a beneficial conversion feature of $90,000 which was recorded as a debt discount. The debt discount was amortized through the maturity dates and a total of $191,080 was amortized to interest expense during the year ended December 31, 2021, which included the unamortized debt discount of $101,080 as of December 31, 2020 and the $90,000 recorded during the year. The remaining unamortized debt discount is $0. The total outstanding principal balance of $295,000 ($205,000 principal balance from 2020 and $90,000 principal balance from 2021) along with accrued interest of $3,569 was converted into 597,139 shares of common stock leaving $0 owed to the service providers and medical advisor as of December 31, 2021. During the year ended December 31, 2021, the Company issued a total of $115,000 in convertible notes to two unaffiliated individuals to pay for operating expenses. The notes were convertible at $0.85 per share provided that in the event the Company issues any shares of common stock before the maturity date at a price that is lower than $0.85 per share, the conversion price shall be reduced to equal such lower issue price per share. The notes had a maturity date of June 30, 2021 and carried an interest rate of 3%. These notes resulted in a beneficial conversion feature of $32,412 which was recorded as a debt discount. The debt discount was amortized through the maturity dates of the notes. A total amount of $32,412 was amortized to interest expense related to these two notes during the year ended December 31, 2021. During the year ended December 31, 2021, the $115,000 principal balance and $397 of accrued interest was converted into 137,996 shares of common stock leaving a balance of $0 owed on the two convertible notes.

Property and Equipment

Property and Equipment	12 Months Ended
Property and Equipment	Dec. 31, 2021
Property and Equipment
Note 5. Property and Equipment	Note 5. Property and Equipment As of December 31, 2021 and December 31, 2020, the balance of property and equipment consisted of the following: December 31, December 31, 2021 2020 Equipment (not placed in service) $ - $ 101,350 Accumulated depreciation - - $ - $ 101,350 During the year ended December 31, 2021, the equipment was fully impaired and $101,350 was written-off. The equipment had not yet been placed in service and therefore depreciation expense for the years ended December 31, 2021 and 2020 was $0 and $0, respectively. During the years ended December 31, 2021 and 2020, the Company acquired property and equipment of $0 and $101,350, respectively.

Issuances of Securities

Issuances of Securities	12 Months Ended
Issuances of Securities	Dec. 31, 2021
Issuances of Securities
Note 6. Issuances of Securities	Note 6. Issuances of Securities Share issuances 2020 During the year ended December 31, 2020, the Company had the following common stock issuances: · 2,000,500 shares of common stock were sold to non-affiliated investors in a private placement for total cash proceeds of $1,130,696 · 50,000 shares of common stock were issued to a former medical advisor for services rendered with a fair value of $47,500 · 250,000 shares of common stock were issued to a consultant for services rendered with a fair value of $153,750 · 125,000 shares of common stock were issued to Mr. Thom, prior to becoming Chief Executive Officer, for services rendered with a fair value of $100,625 · 1,058,634 shares of common stock with a fair value of $866,482 were issued for debt which resulted in a loss on debt settlement of $316,915 · 22,381 shares of common stock were cancelled reducing common stock by $22 and increasing additional paid-in capital by the same amount. Share issuances 2021 During the year ended December 31, 2021, the Company had the following common stock issuances: · A total of 32,490,000 shares of common stock were issued to officers, directors and various consultants related to vesting of RSU’s with a total stock-based compensation cost of $24,467,597. · 2,000,000 shares of common stock were issued to Mr. Beplate as a stock bonus with a stock-based compensation cost of $2,180,000. · 125,000 shares of common stock were sold to an affiliated investor in a private placement for total cash proceeds of $100,000. · 370,455 shares of common stock were sold to non-affiliated investors in a private placement for total cash proceeds of $326,000. · 61,000 shares of common stock were sold to Triton Funds LP (“Triton”) for cash proceeds of $53,802 (see below for discussion of the purchase agreement). · 100,000 shares of common stock were issued for settlement of a business consulting agreement with a fair value of $111,000. · 40,000 shares of common stock with a fair value of $32,800 were issued to consultants for services provided. · 85,000 shares of common stock with a fair value of $69,700 were issued to officers of the Company for services provided (see Note 3). · 25,000 shares of commons stock with a fair value of $26,750 were issued to settle $20,000 of related party advances which resulted in a loss on settlement of debt of $6,750 (see Note 3). · 1,013,085 shares of common stock were issued to settle accrued liabilities – related party worth $561,548 and recorded at market value of $867,368 which resulted in a loss on settlement of debt of $306,220 (see Note 3). · 380,000 shares of common stock with a fair value of $311,600 were issued to settle accrued compensation worth $190,000 which resulted in $121,600 loss of settlement of debt. · 1,085,135 shares of common stock were issued due to the conversion of convertible notes payable and accrued interest of $590,467 (see Note 4) · 1,353,111 shares of common stock were issued due to the conversion of convertible notes payable and accrued interest – related party of $676,555 (see Note 3) · 300,000 shares of common stock were issued for litigation settlement with a fair value of $312,000 · 117,647 shares of common stock were cancelled reducing common stock by $117 and increasing additional paid-in capital by the same amount. Triton Purchase Agreement On June 25, 2021, the Company entered into a common stock purchase agreement (the “Purchase Agreement”) with Triton to sell Triton up to $6,000,000 of common stock. Subject to the terms and conditions of the Purchase Agreement, Triton agreed to purchase from the Company $4,000,000 in value of common shares at closing, based on a purchase price determined by dividing $200,000,000 by the number of outstanding shares of Common Stock, as reported by the Company on its most recently filed Form 10-K or 10-Q. Among customary closing conditions in the Purchase Agreement, closings under the Purchase Agreement may occur after a registration statement covering the resale of the shares which Triton has agreed to purchase from the Company is filed by the Company and declared effective by the SEC, if and when the Company issues a purchase notice to Triton for the number of shares in the purchase notice. Under the terms of the Purchase Agreement, Triton has the right to reduce the amount requested in the purchase notice or not close if the marketplace of the Company’s shares is below a certain threshold at the time of closing. In addition, the Purchase Agreement grants Triton the option to purchase up to $2,000,000 worth of additional shares of common stock at the same purchase price at any time prior to the second anniversary of the closing of the transaction. On June 29, 2021, we filed a registration statement on Form S-3 covering the above shares. The Company’s S-3 registration statement was declared effective by the SEC on September 29, 2021. The market value of the Company’s shares has remained below the level under which Triton is not obligated to complete a purchase of shares. Until such time as the market price for the Company’s shares rises above the threshold price defined in the Purchase Agreement, the Company will not have access to this funding. Restricted stock units As discussed in Note 3, during the year ended December 31, 2020 the Board of Directors approved amendments to the 2019 RSU Agreement. The amendment resulted in 9,960,000 of the RSU’s vesting on January 1, 2021. The fair value of the 9,960,000 RSU’s was $7,071,600. The compensation expense was being amortized on a straight-line basis from the date of the amendment through January 1, 2021 which is the vesting date. Stock-based compensation of $43,121 was recognized as expense during the year ended December 31, 2021. On January 6, 2021, the Board of Directors approved the second amendment to the Restricted Stock Unit Agreement between the Company and Mr. Beplate, former Chief Executive Officer and current Chairman of the Board, in conjunction with Mr. Beplate’s retirement from his day-to-day management role with the Company. The amendment accelerated the vesting and immediately settled his remaining RSU’s by issuing 21,970,000 shares of common stock. Per ASC 718-20-35, the change in vesting conditions resulted in a modification of the stock-based compensation awards. The modification is considered a Type III modification as described in ASC 718-20-55 and resulted in recording $23,947,300 of stock-based compensation expense which was the fair value of the shares on the date of the modification. As discussed in Note 3, during the year ended December 31, 2020, Mr. Thom was granted 11,500,000 RSU’s and Mr. Heaton was granted 500,000 RSU’s. The vesting conditions are contingent upon the achievement of certain Company objectives and milestones which the management is unable to determine when they will be achieved. In April 2021, the Company entered into an RSU agreement with a service provider granting 750,000 RSU’s on the date of the agreement and will grant an additional 750,000 RSU’s, upon the receipt by the Company of an FDA Class III PMA. The 750,000 RSU’s had a grant date fair value of $664,875. The RSUs, subject to certain conditions, shall vest upon the achievement of certain Company objectives and milestones which management is unable to determine when they will be achieved therefore no compensation expense was recognized during the year ended December 31, 2021. During the year ended December 31, 2021, the Company terminated the services of one of its legal counsels who had an RSU agreement in place. Per the RSU agreement, all of the unvested RSU’s owed to the legal counsel vested immediately upon termination of services. This resulted in 325,000 shares of common stock being issued and $230,750 of stock-based compensation being recorded which was the fair value of the shares on the original grant date of the RSU agreement. During the year ended December 31, 2021, the Company recorded the grant of 100,000 RSU’s to one of its legal counsels and 35,000 of the RSU’s vested. The vested RSU’s had a grant date fair value of $26,425 which was recorded as stock-based compensation expense. As discussed in Note 3, Mr. Heaton was granted 500,000 RSU’s in December of 2020 and an additional 500,000 RSU’s in May of 2021. The vesting conditions are contingent upon the achievement of certain Company objectives and milestones. During the year ended December 31, 2021, certain objectives were achieved which resulted in the vesting of 200,000 of RSU’s granted to Mr. Heaton. The 200,000 RSU’s had a grant date fair value of $220,000 which was recorded as stock-based compensation expense. Management is unable to determine if and when FDA approval of a PMA Class III will be awarded to the Company or when a change of control will occur, if at all, and as of December 31, 2021, there was a total of $27,017,200 unrecognized compensation cost related to the restricted stock unit awards. Activity related to our restricted stock units during the year ended December 31, 2020 was as follows: Number of Units Weighted Average Grant Date Fair Value Total awards outstanding at December 31, 2019 50,350,000 $ 0.94 Units granted 62,350,000 $ 0.80 Units Exercised/Released (7,595,000 ) $ 0.71 Units Cancelled/Forfeited (45,775,000 ) $ 0.94 Total awards outstanding at December 31, 2020 59,330,000 $ 0.82 Activity related to our restricted stock units during the year ended December 31, 2021 was as follows: Number of Units Weighted Average Grant Date Fair Value Total awards outstanding at December 31, 2020 59,330,000 $ 0.82 Units granted 23,320,000 $ 1.08 Units Exercised/Released (32,490,000 ) $ 0.97 Units Cancelled/Forfeited (21,970,000 ) $ 0.71 Total awards outstanding at December 31, 2021 28,190,000 $ 0.96

Litigation

Litigation	12 Months Ended
Litigation	Dec. 31, 2021
Litigation
Note 7. Litigation	Note 7. Litigation A Complaint was filed with the United States District Court, Southern District of New York by Steven Safran as Plaintiff against the Company and Douglas Beplate, its CEO, as Defendant. This case was transferred to the United States District Court in Las Vegas, Nevada. Mr. Safran sought damages and monies allegedly owed pursuant to an employment agreement of approximately $734,000 and allegedly unpaid loans of $245,824 provided to Defendants. The Company denied the Plaintiff’s allegations. On July 21, 2021, Mr. Safran and the Defendants entered into a Settlement Agreement and General Release whereby the Company agreed to pay $250,000 in cash and issue 300,000 shares of common stock to Mr. Safran. The 300,000 shares have a fair market value of $312,000. As of December 31, 2021, the 300,000 shares of common stock have been issued and $250,000 in cash has been paid. In March 2021, the Company received payment of $304,273 from Maxim Group LLC, representing the full settlement payment in accordance with a Settlement Agreement in a previously disclosed arbitration between the Company and Maxim that was reached in December 2019. Philip Forman, who served as Chairman, a director, Chief Executive Officer and Chief Medical Advisor of the Company at various times between 2011 and October 2015, filed a lawsuit against the Company and our then-Chief Executive Officer, Douglas Beplate, in the United States District Court of the District of Nevada. The plaintiff has claimed, among other things: that the June 25, 2015 Amendment to his November 10, 2014 Employment Agreement with the Company, which terminated the Employment Agreement on October 1, 2015, is not enforceable due to lack of consideration; that a July 22, 2015 Stock Purchase Agreement pursuant to which the plaintiff sold Company shares issued to him under the Amendment to a third a party is unenforceable (despite the fact that all payment for the shares under the Stock Purchase Agreement was made); that the plaintiff’s 2014 Employment Agreement remains valid and that he is entitled to cash and stock compensation under that Employment Agreement (without giving regard to the Amendment); that if the Amendment is enforceable, he is entitled to the shares issued under the Amendment (without mention that those shares were sold to a third party under the Stock Purchase Agreement described above); and that the Company and Mr. Beplate defrauded the plaintiff relating to the foregoing. The plaintiff is seeking declaratory judgment regarding the parties’ relative rights under the Employment Agreement, the Amendment and the Stock Purchase Agreement; money damages of no less than $2,795,000; and punitive damages of $8,280,000. The Company filed a motion to dismiss the plaintiff’s claims which was denied on March 19, 2020. On May 5, 2021, the plaintiff provided a deposition as instructed by the Court, subsequent to which the Company filed a motion for dismissal of this proceeding . In 2018 an action was commenced in the United States District Court Southern District of New York entitled JEC Consulting Associates, LLC. Liquidator of Lead Dog Capital LP against United Health Products t/k/a United EcoEnergy Corp and Douglas K. Beplate under Docket Number 18-cv-1139 (ER). The third party action sought to remove a restrictive legend from a particular stock certificate for Three Million Fifty Thousand (3,050,000) shares and declare the shares to be free trading. The third party plaintiff alleges that the Company and Mr. Beplate refused to have the restrictive legend on the stock certificate removed under Rule 144 and sought compensatory and punitive damages. The Federal court issued an order that the Securities Exchange Commission should review the claim before the District Court renders a final ruling. Discovery appears to be substantially complete and settlement discussions between the third party plaintiff and the Company have been initiated. Due to uncertainties inherent in litigation, we cannot predict the outcome of the above legal proceedings. The Company has commenced the following legal proceedings: On February 7, 2020, the Company filed the Original Petition for Fraud and Breach of Contract in the Texas District Court for the 215th Judicial District of Harris County against defendants Patterson Companies Inc., Patterson Management, L.P., Patterson Veterinary, Inc. and Patterson Logistics Services, Inc., and Animal Health International, Inc. On March 5, 2020, the defendants removed the case to U.S. District Court for Southern District of Texas. The defendants filed their answer in federal court on March 12, 2020. The original August 25, 2020 pretrial deadlines were extended. On January 18, 2022, the Company’s claims were dismissed, with prejudice, by the court. On February 9, 2022, the Company and Patterson reached an agreement on settlement of Patterson’s counterclaim. The Company agreed to pay $120,000 which has been accrued as of December 31, 2021. The defendants filed a Motion for Summary Judgment which was denied by the court on March 11, 2021. In August 2020, United Health Products filed suit against its former auditors, Haynie & Company, in Utah State Court, asserting claims related to professional negligence and breach of fiduciary duty. Haynie & Company has denied the allegations. Discovery is largely complete and the parties have each submitted a report by their respective expert witness to the Court.

Income Tax

Income Tax	12 Months Ended
Income Tax	Dec. 31, 2021
Income Tax
Note 8. Income Tax	Note 8. Income Tax The Company accounts for income taxes under the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) No. 740, Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company did not take any uncertain tax positions and had no adjustments to its income tax liabilities or benefits pursuant to the provisions of Section 740-10-25 for the years ended December 31, 2021 and 2020. The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. No such interest or penalties were recognized during the period presented. The Company had no accruals for interest and penalties at December 31, 2021 or 2020. The Company’s federal income tax returns for the years ended December 31, 2018 through December 31, 2021 remain subject to examination by the Internal Revenue Service as of December 31, 2021. During 2021 and 2020, the Company incurred net losses and, therefore, has no tax liability. The net deferred tax asset generated by the loss carry-forward has been fully reserved. Net deferred tax assets consist of the following components as of December 31, 2021 and 2020 2021 2020 Deferred tax assets: Net operating loss carryover $ 4,203,500 $ 3,735,500 Accrued related party payroll (14,000 ) (6,200 ) Valuation allowance (4,189,500 ) (3,729,300 ) Net deferred tax asset $ - $ - The income tax provision differs from the amount of income tax determined by applying the U.S federal income tax rate (21%) for the years ended December 31, 2021 and 2020 due to the following: 2021 2020 Book income $ (6,415,300 ) $ (3,299,400 ) Related party accrued payroll (14,000 ) (6,200 ) (Gain) Loss on debt settlement 91,300 66,500 Stock for services and compensation 5,706,400 2,671,800 Interest amortization 127,800 112,500 Inventory write-off 14,600 1,500 Property and equipment write-off 21,300 - Valuation allowance 467,900 453,300 Income tax expense $ - $ - As of December 31, 2021 and 2020, the Company has taxable net loss carryovers of approximately $20.0 and $17.8 million, respectively, that may be offset against future taxable income.

Other Income

Other Income	12 Months Ended
Other Income	Dec. 31, 2021
Other income (expenses)
Note 9. Other income	Note 9. Other Income As described in Note 7 above, during the year ended December 31, 2021, the Company received payment of $304,273 from Maxim Group LLC, as full and final settlement of its previously disclosed arbitration between the Company and Maxim that was settled in December 2019. The $304,273 was recorded as other income in the Statement of Operations.

Subsequent Event

Subsequent Event	12 Months Ended
Subsequent Event	Dec. 31, 2021
Subsequent Event
Note 10. Subsequent Events	Note 10. Subsequent Events The Company has evaluated events from December 31, 2021, through the date whereupon the financial statements were issued and has determined that there are no material events that need to be disclosed, except as follows: The issued a total of 162,662 shares of common stock for the following: · 6,252 shares of common stock were issued to a consultant for the reimbursement of expenses. · 136,410 shares of common stock were sold to unaffiliated investors for total proceeds of $57,292 · 20,000 shares of common stock were issued to legal counsel for services provided The Company received a total of $165,000 in advances from its CEO and $20,000 from a former officer. The Company entered into a $100,000 promissory note. The note accrues interest at 1% and requires monthly payments of $9,136 until the balance is paid in full.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
Significant Accounting Policies (Policies)	Dec. 31, 2021
Significant Accounting Policies
Going Concern	The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred recurring net losses, negative working capital and operations have not provided cash flows. Additionally, the Company does not currently have sufficient revenue producing operations to cover its operating expenses and meet its current obligations. In view of these factors, there is substantial doubt about the Company's ability to continue as a going concern. The Company intends to finance its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital and other business requirements. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. On March 11, 2020, the World Health Organization declared the outbreak of a coronavirus (COVID-19) as a pandemic. As a result, economic uncertainties have arisen which have the potential to negatively impact the Company’s ability to raise funding. Other factors that carry financial implications for the Company could occur although the potential impacts are unknown at this time.
Basis of presentation	The Company prepares its financial statements on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.
Use of Estimates	The preparation of financial statements in conformity with generally accepted accounting principles requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported period. Changes in the economic environment, financial markets, as well as in the healthcare industry, and any other parameters used in determining these estimates, could cause actual results to differ.
Cash and Cash Equivalents	The Company considers all highly liquid debt investments purchased with a maturity of three months or less to be cash equivalents.
Fair Value Measurements	Accounting principles generally accepted in the United States define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Additionally, the inputs used to measure fair value are prioritized based on a three-level hierarchy. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: Level 1 — Quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs other than quoted prices included in Level 1. We value assets and liabilities included in this level using dealer and broker quotations, bid prices, quoted prices for similar assets and liabilities in active markets, or other inputs that are observable or can be corroborated by observable market data. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2021 and 2020. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.
Income Taxes	The Company accounts for income taxes using a method that requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company’s assets and liabilities which is commonly known as the asset and liability method. In assessing the ability to realize deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company evaluates its tax positions taken or expected to be taken in the course of preparing the Company’s tax returns to determine whether the tax positions are ‘‘more-likely-than-not’’ of being sustained by the applicable tax authority. Tax positions not deemed to meet the “more-likely-than-not” threshold are recorded as an expense in the applicable year. The Company does not have a liability for any unrecognized tax benefits. Management’s evaluation of uncertain tax positions may be subject to review and adjustment at a later date based upon factors including, but not limited to, an on-going analysis of tax laws, regulations and interpretations thereof, with due consideration given to the fact that tax periods are open to examination by tax authorities. As of December 31, 2021 and 2020, the Company has approximately $20.0 and $17.8 million of net operating loss carry-forwards, respectively, available to affect future taxable income and has established a valuation allowance equal to the tax benefit of the net operating loss carry forwards and temporary differences as realization of the asset is not assured.
Revenue Recognition	The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers The Company receives orders for its HemoStyp products directly from its customers. Revenues are recognized based on the agreed upon sales or transaction price with the customer when control of the promised goods are transferred to the customer. The transfer of goods to the customer and satisfaction of the Company’s performance obligation will occur either at the time when products are shipped or when the products arrive and are received by the customer depending on the shipping terms. No discounts are offered by the Company as part of payment terms. The Company does not provide an estimate for returns as there is no anticipation for any returns in the normal course of business.
Trade Accounts Receivable and Concentration Risk	We record accounts receivable at the invoiced amount and we do not charge interest. We review the accounts receivable by amounts due from customers which are past due to identify specific customers with known disputes or collectability issues. In determining the amount of the reserve, we make judgments about the creditworthiness of significant customers based on ongoing credit evaluations. We will also maintain a sales allowance to reserve for potential credits issued to customers. We will determine the amount of the reserve based on historical credits issued. There was no provision for doubtful accounts recorded at December 31, 2021 and 2020. The Company recorded $0 in bad debt expense for the years ended December 31, 2021 and 2020. For the year ended December 31, 2021 one customer accounted for 100% of the Company’s net revenue. For the year ended December 31, 2020 one customer accounted for 100% of the Company’s net revenue.
Inventory	Inventory is valued at the lower of cost or net realizable value using the first-in, first-out (FIFO) method. Inventory on the balance sheet consists of raw materials purchased by the Company and finished goods. December 31, 2021 December 31, 2020 Raw materials $ - $ 50,654 Finished goods - 19,020 $ - $ 69,674 During the years ended December 31, 2021 and 2020, the Company determined that $69,649 and $6,979, needed to be impaired and written-off, respectively.
Advertising and Marketing Costs	Advertising and marketing costs are expensed as incurred. The Company incurred $166,510 and $206,572 in advertising and marketing costs during the years ended December 31, 2021 and 2020, respectively.
Shipping and Handling Costs	The Company includes shipping and handling cost as part of cost of goods sold.
Research and Development	The Company charges research and development costs to expense when incurred. The Company incurred $237,458 and $245,218 in research and development expenses during the years ended December 31, 2021 and 2020, respectively.
Stock Based Compensation	The Company accounts for share-based compensation under the provisions of ASC 718, Compensation-Stock Compensation The Company accounts for stock compensation arrangements with non-employees in accordance with Accounting Standard Update (ASU) 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting,
Per Share Information	Basic earnings per share are calculated using the weighted average number of common shares outstanding for the period presented. Diluted earnings per share is computed using the weighted-average number of common shares and, if dilutive, potential common shares outstanding during the period. The dilutive effect of potential common shares is not reflected in diluted earnings per share because the Company incurred a net loss for the years ended December 31, 2021 and 2020 and the effect of including these potential common shares in the net loss per share calculations would be anti-dilutive. The total potential common shares as of December 31, 2021 include 28,190,000 of restricted stock units. The total potential common shares as of December 31, 2020 include 59,330,000 of restricted stock units and 1,867,500 shares of common stock for convertible notes payable – related party.
Property and Equipment	Property and equipment are stated at cost. Depreciation is computed on the straight-line method. The depreciation and amortization methods are designed to amortize the cost of the assets over their estimated useful lives, in years, of the respective assets as follows: Equipment 10 years Maintenance and repairs are charged to expense as incurred. Improvements of a major nature are capitalized. At the time of retirement or other disposition of property and equipment, the cost and accumulated depreciation are removed from the accounts and any gains or losses are reflected in income.
Impairment of Long-lived Assets	The Company applies the provisions of ASC 360, Property, Plant and Equipment, When equipment is sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is included in the results of operations. During the years ended December 31, 2021 and 2020 the Company determined its property and equipment should be impaired and $101,350 and $0 was written off, respectively.
New Accounting Pronouncements	In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) No. ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, Under current GAAP, there are five accounting models for convertible debt instruments. ASU 2020-06 removes from U.S. GAAP the separation models for (1) convertible debt with a cash conversion feature and (2) convertible instruments with a beneficial conversion feature. As a result, after adopting the ASU’s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC 815 or (2) a convertible debt instrument was issued at a substantial premium. Additionally, for convertible debt instruments with substantial premiums accounted for as paid-in capital, the FASB decided to add disclosures about (1) the fair value amount and the level of fair value hierarchy of the entire instrument for public business entities and (2) the premium amount recorded as paid-in capital. ASU 2020-06 will be effective for public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the potential impact of the adoption of this accounting pronouncement to its financial statements. The Company considers all new pronouncements and management has determined that there have been no other recently adopted or issued accounting standards that had or will have a material impact on its financial statements.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
Significant Accounting Policies (Tables)	Dec. 31, 2021
Significant Accounting Policies
Schedule of inventory	December 31, 2021 December 31, 2020 Raw materials $ - $ 50,654 Finished goods - 19,020 $ - $ 69,674
Schedule of property and equipment	Equipment 10 years

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
Property and Equipment (Tables)	Dec. 31, 2021
Property and Equipment
Schedule of property plant and equipment	December 31, December 31, 2021 2020 Equipment (not placed in service) $ - $ 101,350 Accumulated depreciation - - $ - $ 101,350

Issuances of Securities (Tables

Issuances of Securities (Tables)	12 Months Ended
Issuances of Securities (Tables)	Dec. 31, 2021
Issuances of Securities
Schedule of Restricted stock units	Number of Units Weighted Average Grant Date Fair Value Total awards outstanding at December 31, 2019 50,350,000 $ 0.94 Units granted 62,350,000 $ 0.80 Units Exercised/Released (7,595,000 ) $ 0.71 Units Cancelled/Forfeited (45,775,000 ) $ 0.94 Total awards outstanding at December 31, 2020 59,330,000 $ 0.82 Number of Units Weighted Average Grant Date Fair Value Total awards outstanding at December 31, 2020 59,330,000 $ 0.82 Units granted 23,320,000 $ 1.08 Units Exercised/Released (32,490,000 ) $ 0.97 Units Cancelled/Forfeited (21,970,000 ) $ 0.71 Total awards outstanding at December 31, 2021 28,190,000 $ 0.96

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
Income Tax (Tables)	Dec. 31, 2021
Income Tax
Schedule of deferred tax assets	2021 2020 Deferred tax assets: Net operating loss carryover $ 4,203,500 $ 3,735,500 Accrued related party payroll (14,000 ) (6,200 ) Valuation allowance (4,189,500 ) (3,729,300 ) Net deferred tax asset $ - $ -
Schedule of income tax provision	The income tax provision differs from the amount of income tax determined by applying the U.S federal income tax rate (21%) for the years ended December 31, 2021 and 2020 due to the following: 2021 2020 Book income $ (6,415,300 ) $ (3,299,400 ) Related party accrued payroll (14,000 ) (6,200 ) (Gain) Loss on debt settlement 91,300 66,500 Stock for services and compensation 5,706,400 2,671,800 Interest amortization 127,800 112,500 Inventory write-off 14,600 1,500 Property and equipment write-off 21,300 - Valuation allowance 467,900 453,300 Income tax expense $ - $ -

Significant Accounting Polici_4

Significant Accounting Policies (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Significant Accounting Policies
Raw materials	$ 0	$ 50,654
Finished goods	0	19,020
Total inventory	$ 0	$ 69,674

Significant Accounting Polici_5

Significant Accounting Policies (Details 1)	12 Months Ended
Significant Accounting Policies (Details 1)	Dec. 31, 2021
Significant Accounting Policies
Equipment	10 years

Significant Accounting Polici_6

Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Net operating loss carry-forwards	$ 20,000,000	$ 17,800,000
Bad debt expense	0	0
Advertising and marketing costs	166,510	206,572
Write-off of inventory	69,649	6,979
Research and development costs	237,458	$ 245,218
Impaired	$ 101,350
One Customer [Member]
Concentration of credit risk percentage	100.00%	100.00%
Restricted Stock Units [Member]
Impaired	$ 101,350	$ 0
Convertible loans Payable shares, related party		1,867,500
Potential antidilutive shares	28,190,000	59,330,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	May 15, 2021	Jan. 06, 2021	Jul. 15, 2020	Jan. 02, 2021	Nov. 30, 2020	Jul. 21, 2020	Jul. 20, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2018	Apr. 22, 2019	Apr. 15, 2019
Total vesting			6,795,000
Fair market value								$ 262,605
Number of shares, forfeited									425,000
Shares forfeited, value									$ 70,567
Stock-based compensation expense								2,021,000	7,028,480	$ 0
Beneficial conversion feature								234,912	909,565
Loan from related party								245,500	251,730
Convertible loans payable - related parties								0	456,032
Accrued liabilities - related party								3,207	193,651
Interest expense related party								392,112	336,203
Remaining unvested RSU's value								301,750
Interest expense								$ 226,139	$ 210,025
Common stock shares issued								228,667,229	189,357,090
Stock based compensation								$ 26,861,097	$ 12,722,805
Debt discount amortization								608,710	535,766
Converted loans payable and accrued liabilities								$ 0	103,920
Shares issued								597,139
Accrued compensation								$ 45,000
Paid to related party								219,000	0
Operating expenses								29,800,669	14,849,099
Amendment To RSU Agreements [Member]
Fair market value								$ 69,700
Common stock shares issued								85,000
Restricted stock units, description						The July 21 amendment also changed the vesting terms so that 15% of RSUs vested on July 15, 2020, an additional 15% of RSU units upon FDA approval of a PMA Class III awarded to the Company, an additional 20% of RSU units on January 1, 2021 and the balance of all unvested RSU units on the earliest date that (a) the Company achieves $20 million in gross cumulative sales commencing as of January 1, 2020, (b) a Covered Transaction is consummated or (c) a Trigger Event occurs. Each Grantee has the option to delay the Vesting Date of all or part of his RSUs until no later than an event described in (b) or (c) above, by serving written notice to the Company prior to such Vesting Date.
Restricted stock unites increased description						The approved amendments increased the amount of RSU’s granted to Mr. Beplate from 33,000,000 to 33,800,000, increased the amount of RSU’s granted to Mr. Schiliro from 8,000,000 to 10,000,000, increased the amount of RSU’s granted to Mr. Heaton from 50,000 to 500,000, increased the amount of RSU’s granted to the office administrator, who is a person affiliated with the Company’s former CEO from 250,000 to 500,000 and increased the amount of RSU’s granted to the Technical Product Supervisor, who is the son of the former office administrator from 250,000 to 500,000.
Mr. Beplate [Member]
Total vesting			1,500,000
Beneficial conversion feature									$ 100,000
Stock based compensation		$ 26,127,300						$ 2,180,000
Common stock share issued		2,000,000		6,760,000
Increased amount of RSU's granted						33,800,000
Restricted stock units granted		21,970,000						2,000,000	6,760,000
Converted loans payable and accrued liabilities									$ 100,000
Convertible notes per share									$ 0.50
Amount owed								$ 0	$ 74,056
Interest Rate									3.00%
Maturity Date									Mar. 31, 2021
Shares issued			507,000
Shares issued for services, shares								2,000,000
Accrued compensation								$ 0	$ 0
Gross cumulative sales						$ 20,000,000
Debt forgiveness									8,395
Paid to related party									188,375
Loans payable - related parties								657,500	251,730
Brian Thom [Member]
Fair market value								221,400	100,625
Beneficial conversion feature								45,000	338,105
Loan from related party									$ 450,000
Convertible loans payable - related parties								$ 175,000
Common stock shares issued								30,000
Common stock share issued								30,000
Restricted stock units granted									125,000
Converted loans payable and accrued liabilities								$ 450,000	$ 105,000
Principal balance								$ 600,000	$ 555,000
Convertible notes per share								$ 0.50	$ 0.5
Amount owed								$ 899	$ 0
Debt settlement								86,400
Unamortized Debt Discount								$ 0	$ 199,314
Interest Rate								3.00%	3.00%
Maturity Date								Mar. 31, 2021	Mar. 31, 2021
Debt Discount								$ 45,000	$ 138,792
Restricted stock units, vesting					11,500,000
Shares issued for services, shares								1,220,272	125,000
Accrued compensation								$ 45,000	$ 105,000
Loan of debt discount								45,000	555,000
Accrued interest								10,135
Amortized Debt Discount								244,314	$ 199,314
Restricted stock units granted fair market value									100,625
Accrued compensation settled								$ 135,000
Shares issuance of common stock								270,000
Technical Product Supervisor [Member]
Increased amount of RSU's granted						500,000
Shares issued for services, shares								50,000
Officers And Directors [Member]
Stock based compensation								$ 24,467,597
Shares issued								1,000,000
Shares issued for services, shares								32,490,000
Chief Executive Officers [Member]
Restricted stock units, vesting								50,000
Shares issued for services, shares								50,000	125,000
Office Administrator [Member]
Total vesting			50,000
Increased amount of RSU's granted						500,000
Restricted stock units, vesting			6,845,000					500,000
Shares issued			75,000
Reimbursable expenses								$ 10,330	$ 0
Shares issued for services, shares								50,000
Repayment of related party								$ 60,000	45,000
Stock-based compensation, shares			4,859,950
Louis Schiliro [Member]
Total vesting			75,000
Beneficial conversion feature								$ 45,000	174,985
Loan from related party									130,000
Convertible loans payable - related parties									110,000
Accrued liabilities - related party									1,028
Interest expense									105,331
Common stock shares issued								30,000
Common stock share issued				2,000,000				25,000
Increased amount of RSU's granted						10,000,000
Restricted stock units granted								2,000,000
Converted loans payable and accrued liabilities								$ 45,000	$ 150,000
Convertible notes per share								$ 0.50	$ 0.50
Amount owed								$ 0	$ 59,467
Unamortized Debt Discount									$ 69,654
Interest Rate								3.00%	3.00%
Maturity Date								Mar. 31, 2021	Mar. 31, 2021
Debt Discount									$ 105,331
Restricted stock units, vesting			75,000				50,000
Reimbursable expenses								$ 0	59,467
Shares issued for services, shares								80,173
Repayment of related party								$ 30,000
Accrued compensation								45,000	150,000
Loans payable - related parties									110,000
Advanced								34,000
Operating expenses								30,000
Loan of debt discount								25,000	170,000
Accrued interest								1,502
Remaining balance								44,000	0
Amortized Debt Discount								114,654
Compensation payment									0
Shares deposited in escrow										5,000,000
Stock-based compensation expense									30,000
Kristofer Heaton [Member]
Total vesting			75,000
Beneficial conversion feature								22,500	3,750
Convertible loans payable - related parties								22,500	3,750
Accrued liabilities - related party								2,308	7,503
Interest expense related party								2,308	336,203
Interest expense								$ 6,894	8,925
Common stock shares issued								25,000
Stock based compensation								$ 220,000
Fair market value								69,700
Debt discount amortization								$ 385,218	$ 327,278
Common stock share issued				100,000				85,000
Increased amount of RSU's granted						500,000
Additional RSU's issued									1,000,000
Additional Restricted stock units granted	500,000							500,000
Restricted stock units granted								100,000	6,760,000
Converted loans payable and accrued liabilities									$ 3,750
Principal balance								$ 26,250
Convertible notes per share								$ 0.50	$ 0.50
Amount owed								$ 0
Debt settlement								$ 104,980
Unamortized Debt Discount									$ 3,750
Interest Rate									3.00%
Maturity Date								Mar. 31, 2021	Mar. 31, 2021
Debt instrument converted to shares								52,666
Debt Discount								$ 22,500	$ 22,500
Restricted stock units, vesting								200,000
Shares issued								320,250
Reimbursable expenses								$ 52,625	52,625
Payment of compensation								105,000	0
Kristofer Heaton [Member] \| Convertible Notes Payable [Member]
Interest expense related party								$ 392,112
Douglas Beplate [Member]
Beneficial conversion feature									83,156
Convertible loans payable - related parties									$ 456,032
Common stock shares issued									410,000
Restricted stock units granted								6,760,000	6,760,000
Converted loans payable and accrued liabilities									$ 205,000
Convertible notes per share									$ 0.65			$ 0.65
Debt Discount									$ 365,785
Payment of compensation									0
Repayment of related party								$ 161,135	505,765
Debt forgiveness									24,000
Loans payable - related parties								657,500	251,730
Stock-based compensation expense								$ 26,127,300
RSU granted to officers, directors and consultants								2,000,000
Stock price per share											$ 0.90
Legal counsel services									87,750
Douglas Beplate [Member] \| April 15, 2019 through December 31, 2019 [Member]
Beneficial conversion feature								$ 315,046
Loan from related party								490,500
Convertible loans payable - related parties									$ 365,785
Convertible notes per share									$ 0.65
Unamortized Debt Discount									$ 0
Mr. Nate Knight [Member]
Amount owed								74,056
Debt settlement								$ 8,368
Restricted stock units, vesting								1,600,000
Reimbursable expenses									7,456
Payment of compensation									42,500
Accrued compensation								$ 0	74,056
Stock-based compensation expense									$ 12,500
Fair market values								$ 82,425
Shares of common stock settlement, shares								78,500

Convertible Notes (Details Narr

Convertible Notes (Details Narrative) - USD ($)	12 Months Ended
Convertible Notes (Details Narrative) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accrued interest	$ 397
Shares of common stock	137,996
Convertible notes payable, net of debt discount	$ 0	$ 103,920
Debt instrument, conversion of shares	597,139
Common stock value for service provider	$ 0
Accrued compensation	45,000
Loan Balance	298,778
Debt instrument, principal balance	295,000	205,000
Beneficial conversion feature	234,912	909,565
Legal Counsel [Member]
Accrued compensation	3,569	$ 45,000
Debt instrument, principal balance	175,000
Maturity Date		Mar. 31, 2021
Debt instrument debt discount		$ 45,000
Price per share		$ 0.50
Interest Rate		3.00%
Beneficial conversion feature		$ 45,000
Common stock value for service provider	$ 176,502
Debt instrument, conversion of shares	350,000	557,056
Interest Expense	$ 1,502	$ 1,537	$ 0
Two Unaffiliated Individuals [Member]
Maturity Date	Jun. 30, 2021
Price per share	$ 0.85
Interest Rate	3.00%
Beneficial conversion feature	$ 32,412
Interest Expense	32,412
Proceeds from convertible notes payable	115,000
Medical advisor [Member]
Convertible notes payable, net of debt discount	115,000	103,920
Accrued compensation	90,000
Debt instrument, principal balance	$ 90,000	205,000
Accrued compensation, convertible notes		$ 205,000
Maturity Date	Mar. 31, 2021	Mar. 31, 2021
Debt instrument debt discount	$ 90,000	$ 101,080
Price per share	$ 0.50	$ 0.50
Lower price per share	0.85
Unamortized debt discount	$ 0
Interest Rate	3.00%	3.00%
Amortization debt discount	$ 191,080
Beneficial conversion feature	$ 90,000	$ 90,000

Property And Equipment (Details

Property And Equipment (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Property and Equipment
Equipment (not placed in service)	$ 0	$ 101,350
Accumulated Depreciation	0	0
Equipment	$ 0	$ 101,350

Property And Equipment (Detai_2

Property And Equipment (Details Narrative) - USD ($)	12 Months Ended
Property And Equipment (Details Narrative) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Property and Equipment
Depreciation expense	$ 0	$ 0
Property and equipment	0	$ 101,350
Impaired	$ 101,350

Issuances of Securities (Detail

Issuances of Securities (Details) - $ / shares	12 Months Ended
Issuances of Securities (Details) - $ / shares	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Issuances of Securities (Details)
Number of units total awards outstanding, beginning	59,330,000	50,350,000
Number of units granted	23,320,000	62,350,000	50,350,000
Number of units exercised/released	(32,490,000)	(7,595,000)
Number of units cancelled/forfeited	(21,970,000)	(45,775,000)
Number of units total awards outstanding, ending	28,190,000	59,330,000	50,350,000
Weighted Average Grant Date Fair Value
Weighted average total awards outstanding, beginning	$ 0.82	$ 0.94
Weighted average units granted	1.08	0.80	$ 0.94
Weighted average units exercised/released	0.97	0.71
Weighted average units cancelled/forfeited	0.71	0.94
Weighted average total awards outstanding, ending	$ 0.96	$ 0.82	$ 0.94

Issuances of Securities (Deta_2

Issuances of Securities (Details Narrative) - USD ($)	Jan. 06, 2021	Jun. 25, 2021	May 31, 2021	Apr. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Common stock shares cancellations						22,381
Increasing additional paid-in capital						$ 22
Fair value of debt						866,482
Loss on debt settlement						316,915
Unrecognized compensation cost					$ 27,017,200
Loss on settlement of debt					(434,570)	(316,521)
Proceeds from issuance of cost					479,802	1,130,696
Related party advances					245,500	251,730
Stock based compensation expense					26,861,097	$ 12,722,805
Common stock, shares issued for service renderred, amount					$ 867,368
January 1, 2021 [Member]
Restricted stock units, vesting					9,960,000
Stock based compensation expense					$ 43,121
Fair value of restricted stock units					$ 7,071,600
Unvested restricted stock units					9,960,000
Mr. Heaton [Member]
Restricted stock units, vesting					200,000
Restricted stock units granted			500,000		500,000	500,000
Stock based compensation expense					$ 220,000
Fair value of restricted stock units					$ 200,000
Consultant [Member]
Common stock shares issued during the period					6,252
Common stock, shares issued for service renderred, shares					40,000	250,000
Common stock, shares issued for service renderred, amount					$ 32,800	$ 153,750
Legal Counsels [Member]
Fair value of vesting					$ 26,425
Common stock, shares issued for service renderred, shares					325,000
Restricted stock units, vesting					35,000
Restricted stock units granted					100,000
Stock based compensation expense					$ 230,750
Litigation Settlement [Member]
Common stock shares issued during the period					300,000
Fair value of common stock					$ 312,000
Convertible Notes Payable [Member]
Common stock shares issued during the period					1,085,135
Accrued interest					$ 590,467
Convertible Notes Payable 1 [Member]
Common stock shares issued during the period					1,353,111
Accrued interest					$ 676,555
Mr. Beplate [Member]
Common stock, shares issued for service renderred, shares					2,000,000
Stock based compensation expense	$ 26,127,300				$ 2,180,000
Officers And Directors [Member]
Common stock, shares issued for service renderred, shares					32,490,000
Stock based compensation expense					$ 24,467,597
Chief Executive Officers [Member]
Common stock, shares issued for service renderred, shares					50,000	125,000
Restricted stock units, vesting					50,000
Common stock, shares issued for service renderred, amount						$ 100,625
Medical advisor [Member]
Common stock, shares issued for service renderred, shares						50,000
Common stock, shares issued for service renderred, amount						$ 47,500
Non Affiliated Investor [Member] \| Private Placement [Member]
Common stock shares issued during the period					370,455	2,000,500
Proceeds from issuance of cost					$ 326,000	$ 1,130,696
Officers [Member]
Common stock, shares issued for service renderred, shares					85,000
Common stock, shares issued for service renderred, amount					$ 69,700
Affiliated Investor [Member] \| Private Placement [Member]
Proceeds from issuance of cost					$ 100,000
Common stock, shares issued for service renderred, shares					125,000
Triton Funds LP [Member]
Proceeds from issuance of cost					$ 53,802
Common stock, shares issued for service renderred, shares					61,000
Common stock purchase agreement description		Triton up to $6,000,000 of common stock. Subject to the terms and conditions of the Purchase Agreement, Triton agreed to purchase from the Company $4,000,000 in value of common shares at closing, based on a purchase price determined by dividing $200,000,000 by the number of outstanding shares of Common Stock, as reported by the Company on its most recently filed Form 10-K or 10-Q.
Additional shares of common stock		$ 2,000,000
Share Issuances [Member]
Common stock shares issued during the period					1,013,085
Accrued liabilities related party					$ 561,548
Loss on settlement of debt					306,220
Proceeds from issuance of cost					$ 867,368
Share Issuances 2021 [Member]
Common stock shares issued during the period					25,000
Loss on settlement of debt					$ 6,750
Proceeds from issuance of cost					26,750
Related party advances					$ 20,000
Share Issuances 1 [Member]
Common stock shares issued during the period					380,000
Loss on settlement of debt					$ 121,600
Accrued compensation					190,000
Fair value of common stock					311,600
Consultant Agreement [Member]
Fair value of common stock					$ 111,000
Common stock, shares issued for service renderred, shares					100,000
Restricted Stock Units [Member]
Restricted stock units granted					11,500,000
Restricted stock units, description				RSU agreement with a service provider granting 750,000 RSU’s on the date of the agreement and will grant an additional 750,000 RSU’s, upon the receipt by the Company of an FDA Class III PMA. The 750,000 RSU’s had a grant date fair value of $664,875.	The amendment accelerated the vesting and immediately settled his remaining RSU’s by issuing 21,970,000 shares of common stock. Per ASC 718-20-35, the change in vesting conditions resulted in a modification of the stock-based compensation awards. The modification is considered a Type III modification as described in ASC 718-20-55 and resulted in recording $23,947,300 of stock-based compensation expense which was the fair value of the shares on the date of the modification.
Common Stock [Member]
Common stock shares cancellations					117,647
Increasing additional paid-in capital					$ 117
Common stock shares issued during the period					162,662	1,058,634

Litigation (Details Narrative)

Litigation (Details Narrative) - USD ($)	12 Months Ended
Litigation (Details Narrative) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	Jul. 21, 2021
Accrued	$ 120,000
Common stock shares issued	228,667,229	189,357,090
Other income	$ 304,273	$ 0
Lead Dog Capital LP [Member]
Loss contingency damages sought, description	in the United States District Court Southern District of New York entitled JEC Consulting Associates, LLC. Liquidator of Lead Dog Capital LP against United Health Products t/k/a United EcoEnergy Corp and Douglas K. Beplate under Docket Number 18-cv-1139 (ER). The third party action sought to remove a restrictive legend from a particular stock certificate for Three Million Fifty Thousand (3,050,000) shares and declare the shares to be free trading
Steven Safran [Member] \| Employment Agreement [Member]
Litigation settlement, damages sought	$ 734,000
Steven Safran [Member] \| Unpaid Loans [Member]
Litigation settlement, damages sought	245,824
Steven Safran [Member] \| Settlement Agreement [Member]
Litigation settlement, amount payable under agreement	$ 250,000		$ 250,000
Common stock shares issued	300,000
Litigation settlement, shares issued	300,000
Litigation settlement, shares issuable under agreement			300,000
Litigation settlement, shares issuable under agreement, fair value			$ 312,000
Former Chief Executive Officer and Chief Medical Advisor [Member]
Compensatory damages	$ 2,795,000
Loss contingency damages sought, punitive damages	8,280,000
Maxim Group LLC [Member]
Other income	304,273
Maxim Group LLC [Member] \| March 2021 [Member]
Other income	$ 304,273

Income Tax (Details)

Income Tax (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Net operating loss carryover	$ 4,203,500	$ 3,735,500
Accrued related party payroll	(14,000)	(6,200)
Valuation allowance	(4,189,500)	(3,729,300)
Deferred tax asset, net	$ 0	$ 0

Income Tax (Details 1)

Income Tax (Details 1) - USD ($)	12 Months Ended
Income Tax (Details 1) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Income Tax
Book income	$ (6,415,300)	$ (3,299,400)
Related party accrued payroll	(14,000)	(6,200)
Loss on debt settlement	91,300	66,500
Stock based compensation	5,706,400	2,671,800
Interest amortization	127,800	112,500
Inventory write-off	14,600	1,500
Property and equipment write-off	21,300	0
Valuation allowance	467,900	453,300
Income tax expense	$ 0	$ 0

Income Tax (Details Narrative)

Income Tax (Details Narrative) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Income Tax
Net loss carryovers	$ 20	$ 17.8

Other Income (Details Narrative

Other Income (Details Narrative) - USD ($)	12 Months Ended
Other Income (Details Narrative) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Other income	$ 304,273	$ 0
Maxim Group LLC [Member]
Other income	$ 304,273

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	12 Months Ended
Subsequent Events (Details Narrative) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Monthly payments	$ 9,136
Promissory note	$ 100,000
Accrues interest	1.00%
CEO [Member]
Received in advanced	$ 165,000
Former Officer [Member]
Received in advanced	$ 20,000
Legal Counsel [Member]
Common shares issued	20,000
Consultant [Member]
Common shares issued	6,252
Unaffiliated Investors [Member]
Common shares issued	136,410
Total proceeds	$ 57,292
Common Stock [Member]
Common shares issued	162,662	1,058,634